Nuvectis Pharma (NVCT) Earnings Analysis
Nuvectis Pharma (NVCT) has no confirmed upcoming earnings date. Last quarter (2026-02-11) it missed with EPS -0.31 USD vs -0.26 USD est (-19.2%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E -14.73.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NVCT next report earnings?
No confirmed upcoming earnings date is currently scheduled for NVCT. This page updates as the calendar is published.
NVCT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-11 | -0.31 USD | -0.26 USD | -19.2% | Miss |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
NVCT valuation and analyst view
| Trailing P/E | -14.73 |
|---|---|
| Trailing EPS | -1.15997 USD |
| Price / book | 31.76 |
| Dividend yield | 0.00% |
| Market cap | 0.51B |
| Analyst consensus | Buy (3 buy / 0 hold / 0 sell) |
| Avg price target | 28.33 USD |
Related research pages
Frequently asked questions
When is Nuvectis Pharma (NVCT)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for NVCT. This page updates as the calendar is published.
Did NVCT beat earnings last quarter?
In its 2026-02-11 report, NVCT posted EPS of -0.31 USD versus a -0.26 USD estimate — a miss of 19.2%.
What is NVCT's earnings track record?
Over the last 1 reported quarters with consensus data, NVCT beat estimates 0 times (0%).
What is NVCT's current P/E ratio and EPS?
NVCT trades at a trailing P/E of -14.73 on trailing EPS of -1.1599662174787178 USD.
What do analysts rate NVCT?
Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 28.33 USD.